Clinical Research Papers:

Greater efficacy of intracavitary infusion of bevacizumab compared to traditional local treatments for patients with malignant cavity serous effusion

Dawei Chen, Xinyu Song, Fang Shi, Hui Zhu, Haiyong Wang, Nasha Zhang, Yan Zhang _, Li Kong and Jinming Yu

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:35262-35271. https://doi.org/10.18632/oncotarget.13064

Metrics: PDF 2793 views  |   HTML 2691 views  |   ?  


Dawei Chen 1,2,*, Xinyu Song 2,3,*, Fang Shi2,3, Hui Zhu2,3, Haiyong Wang2, Nasha Zhang2, Yan Zhang2,3, Li Kong2,3 and Jinming Yu2,3

1 Weifang Medical University, Weifang, China

2 Department of Radiotherapy, Shandong Cancer Hospital Affiliated to Shandong University, Jinan, China

3 School of Medicine and Life Sciences, University of Jinan – Shandong Academy of Medical Sciences, Jinan, China

* These authors have contributed equally to this work

Correspondence to:

Yan Zhang, email:

Li Kong, email:

Jinming Yu, email:

Keywords: malignant serous cavity effusion, intracavitary, bevacizumab, chemotherapy, biological response modifiers

Received: June 30, 2016 Accepted: October 28, 2016 Published: November 03, 2016


Intracavitary infusion of bevacizumab is one effective treatment for malignant serous cavity effusion (MSCE). In this study, we retrospectively evaluated the efficacy of local treatments in 996 advanced cancer patients with MSCE who received paracentesis and intracavitary bevacizumab, or chemotherapy, biological response modifiers, or simple puncture to drain the effusion. The median progression-free survival (PFS) time in patients treated with bevacizumab was 189 days (range, 13-522 days), which was longer than in patients who received one of the other three treatments (p < 0.05). Subgroup analysis revealed that intracavitary infusion of bevacizumab was advantageous for patients with malignant pleural, pericardial, or peritoneal effusions. The median PFS in patients receiving intracavitary bevacizumab did not significantly differ from that of patients receiving a combination of intracavitary and intravenous bevacizumab. Thus the efficacy did not depend on whether patients received intravenous bevacizumab. Only mild related adverse events were observed in all cases, and they did not differ between groups. Proteinuria (severity grade < 3) was most likely to occur in patients who received a combination of intracavitary and intravenous bevacizumab, but no obvious symptoms were observed. Thus, intracavitary infusion of bevacizumab was effective for controlling MSCE without apparent toxicity.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 13064